Correction to: Leukemia https://doi.org/10.1038/s41375-021-01501-0, published online 29 January 2022
We noted a mistake in the Introduction section in the following sentence: “and ability to differentiate therapeutic monoclonal antibodies from endogenous M proteins based on unique retention time and mass”. The use of mass and retention time is actually not true for the MALDI method. We would like to correct this sentence and replace it with: “with ability to aid in differentiating therapeutic monoclonal antibodies from endogenous M proteins on the basis of mass to charge”.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Abdallah, N., Murray, D., Dispenzieri, A. et al. Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. Leukemia 36, 1449 (2022). https://doi.org/10.1038/s41375-022-01567-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-022-01567-4
